Trim AMGN 25-30% at $420+ extended levels; preserve Q2 fundamental inflection and dividend while re-engaging on RSI reset and momentum confirmation at $385-410
The 25-30% trim is the correct calibration—large enough to honor the Underweight-default lesson and harvest meaningful extension risk, modest enough to preserve participation in the genuine Q2 fundamental inflection (operating leverage, FCF generation, margin expansion) and avoid over-trimming into a catalyst-driven re-rating toward the $470 price target. The aggressive "initiate now" framing is rejected as momentum chasing; the conservative "wait for $385 only" is rejected as ignoring opportunity cost; symmetric Hold is rejected as the structurally weakest middle. Re-engagement is contingent on the catalyst stack validating and momentum indicators resetting.
| Position | Action |
|---|---|
| Current price $420+ with confirmed lower-high formation and 22%+ extension above 200 SMA | Trim existing position by 25-30% |
| Price reaches Tier 1 zone ($385-395) with RSI reset <55 and forward EPS revisions stabilizing | Re-engage at 25-33% of original intended size |
| Price reaches Tier 2 zone ($400-410) with confirmed close above 20 SMA on volume >2.5M | Add another 25-33% of original intended size |
AMGN's Q2 2026 blowout results—revenue $10.05B (+9.5%), net income $2.38B (+66%), EPS $4.37 (+65%)—demonstrate that operating leverage from the Horizon integration is finally flowing through, and the current pullback represents a high-probability entry opportunity before upcoming catalysts like Tezspire EoE label expansion get fully priced in.
| Indicator | Value | Signal |
|---|---|---|
| Close | 429.88 | neutral |
| 10 EMA | 431.79 | bearish |
| 50 SMA | 385.89 | bullish |
| 200 SMA | 351.46 | bullish |
| RSI (14) | 62.41 | neutral |
| MACD | 16.00 | neutral |
| MACD Signal | 16.44 | bearish |
| MACD Histogram | -0.44 | bearish |
| Bollinger Middle (20 SMA) | 419.65 | neutral |
| Bollinger Upper | 456.75 | bearish |
| Bollinger Lower | 382.54 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $400-410 zone with confirmed close above 20 SMA on volume >2.5M
Then: Add another 25-33% of original intended size
Valuation is attractive with significant multiple compression expected
↩ rebuts: “The P/E appears premium but the forward multiple is attractive given the earnings trajectory”
EV: +$28+ (from $419-$420 entry to $447+ target) · concedes: Q3 2025 one-time $400M intangibles impairment was absorbed and fully reflected in results; LLY competes in GLP-1/obesity while AMGN competes in immunology (Tezspire, Otezla, Tremfya)—different therapeutic lanes; The 50 SMA at ~$385 is the technical line in the sand—only a break here breaks the trend
AMGN at all-time highs with a 0.77:1 risk/reward, 2.29 PEG ratio, and a $43B debt load in a hawkish Fed regime is a "do not initiate" until technicals reset and valuation compresses.
· concedes: Q2 2026 operating income growth (32%) is real—Horizon synergies are flowing through; Repatha 20% mortality reduction in 12,000 patients is genuinely positive incremental franchise extension; AMGN is not a short candidate into a confirmed uptrend; The $351 200 SMA retest would be a longer-term mean-reversion buy opportunity
→ vs conservative: The '22% above 200 SMA' metric is oversimplified — a stock 22% above its 200 SMA with golden cross intact, all moving averages rising, and 10 EMA above 50 SMA above 200 SMA is a structural uptrend, not a topping pattern. Historical data does not support the claim that accelerating earnings and expanding gross margins roll over simply from extended price relative to a long-term moving average.
→ vs conservative: The 'wait for Tier 1 at $385-$395' framework is chasing a moving target — the 50 SMA at $385.89 is rising, so by the time price reaches that level, the relevant price may already be $400. Requiring a 10% retracement before owning a stock with $8.6B FCF, two Phase 3 wins, and confirmed golden cross is superstition, not discipline.
→ vs neutral: The MACD cross below signal line is a momentum cooldown from overbought readings, not a momentum breakdown. The MACD line at +16 remains well above zero, and in strong uptrends MACD whipsaws around the signal line constantly without breaking the trend.
→ vs neutral: The 'respect short-term momentum loss' framework misses that the August 25 high at $447 was made on genuine fundamental news flow, not retail froth. Zero Reddit chatter across all investing subreddits confirms this is institutional accumulation, not a meme-stock blowoff top.
→ vs conservative: No explicit bearish thesis justifies zero new capital deployment — drug pricing overhang is already priced in (AMGN trades at a discount to peers), patent cliff on Prolia/Enbrel is being replaced by Tezspire EoE and Repatha mortality data, and the $57B debt load is investment-grade quality at 2.5x net debt to EBITDA for a company generating $8.6B annual FCF.
→ vs neutral: The 'avoid current $420+ levels' instruction is leaving easy money on the table. A 50% allocation at current levels with hard stop at $380 gives asymmetric setup — risking $50 to capture $40-50 on first leg with catalyst-driven re-rating optionality beyond that.
| bullish |
| ATR | 10.23 | neutral |
| Volume | 2.31M | neutral |
Support: 431.79 · 419.65 · 385.89 · 382.54 · 351.46 | Resistance: 447.03 · 456.75
AMGN is in a strong long-term uptrend with a perfect bullish MA stack (10 EMA > 50 SMA > 200 SMA), but is experiencing a short-term pullback from its Aug 25 all-time high of $447.03. The MACD line crossed below its signal line on Aug 31, with histogram at -0.44 — the first negative reading since early July — signaling momentum deceleration. Price closed below the 10 EMA for the first time since mid-July, though key support at the 20 SMA ($419.65) and 50 SMA ($385.89) remain intact. RSI has cooled from 79.80 (overbought on Aug 19) to 62.41, leaving room for either continuation or further pullback. The recommendation is to HOLD existing long positions with stops beneath the 20 SMA, and wait for mean-reversion entries near $419–$420 or momentum resumption above $432 for new positions. The rating is HOLD.
Market Cap
$232.4 B
Current Price
~$429.80
P/E Ratio (TTM)
26.72x
Forward P/E
17.62x
PEG Ratio
2.29
Price / Book
19.88x
EPS (TTM)
$16.09
Forward EPS
$24.40
Dividend Yield
2.33%
Beta
0.413
52-Week High
$447.03
52-Week Low
$269.77
50-Day MA
$387.89
200-Day MA
$355.93
Revenue (TTM)
$38.09 B
Gross Profit (TTM)
$27.39 B (71.9%)
EBITDA (TTM)
$17.27 B (45.3%)
Operating Income (TTM)
$13.55 B (35.5%)
Net Income (TTM)
$8.74 B (22.9%)
Total Assets (Q2'26)
$95.64 B
Cash & Equivalents (Q2'26)
$13.99 B
Total Debt (Q2'26)
$57.30 B
Net Debt (Q2'26)
$43.32 B
Stockholders' Equity (Q2'26)
$11.69 B
Tangible Book Value
−$27.47 B
Current Ratio
1.37
Working Capital
$9.46 B
Operating CF (TTM)
~$12.78 B
CapEx (TTM)
~$2.30 B
Free Cash Flow (TTM)
$8.65 B
FCF Yield
3.7%
Dividends Paid (TTM)
~$5.4 B/yr
Dividend Payout Ratio
~63%
ROE
91.5%
ROA
8.7%
Net Debt / TTM EBITDA
2.5x
Interest Coverage (EBIT/Interest)
~5.2x
R&D Spend (TTM run-rate)
~$7.6 B
SG&A (TTM run-rate)
~$7.2 B
Q2 2026 Revenue
$10.05 B (+9.5% YoY)
Q2 2026 Operating Income
$3.51 B (+32.3% YoY)
Q2 2026 Net Income
$2.38 B (+66% YoY)
Q2 2026 Diluted EPS
$4.37 (+65% YoY)
Q2 2026 FCF
$3.49 B
FY2025 Revenue
$36.75 B (+10.0% YoY)
FY2025 Net Income
$7.71 B (+88% YoY)
FY2025 Diluted EPS
$14.23
FY2025 Gross Margin
67%
Goodwill
~$18.7 B
Intangibles
$20.5 B
Strengths
Concerns
Amgen is a high-quality, defensive large-cap biotech executing well post-Horizon integration, with accelerating top-line growth (Q2 2026 revenue +9.5% YoY, net income +66% YoY), expanding margins (gross margin 71.9% TTM), and robust free cash flow generation of $8.65B TTM. The company is actively deleveraging (net debt down $10B since the Horizon deal to $43.32B) while simultaneously growing its dividend (2.33% yield, 63% payout ratio). However, premium valuation (P/E 26.7x TTM, 17.6x forward; P/B 19.9x), $57.3B in total debt, and patent cliff risks on legacy assets like Enbrel and Prolia represent key risks to monitor. The forward EPS growth trajectory of 52% (from $16.09 TTM to $24.40) provides the primary catalyst for upside.
Macro: Sharp repricing toward Fed rate hikes in 2026: 71% Polymarket-implied probability (up 14.5pp week-over-week), 56% for September 2026 meeting (+22pp), 64% for October 2026 (+24pp); only 1% for a cut by September 2026. Soft landing remains base case with 8% U.S. recession odds by end-2026. Market shifting from 'dovish pivot' to 'higher for longer/re-tightening' regime. Geopolitical risk elevated (Middle East strikes renewing), adding safe-haven bid into gold; equities with defensive cash flows relatively resilient.